Medtech M&A Is Thriving, Reports McKinsey

The Firm Expects An Upswing in M&A Activity In 2025

 
• By Natasha Barrow

Only one year in the last decade involved more medtech acquisitions worth over $1bn than 2024, said McKinsey. A new report from the consulting firm found that despite an overall fall in activity for the life science sector, the economic and regulatory environment may support a strong rebound in dealmaking.

M&A
(Shutterstock)

Merger and acquisition (M&A) activity in the medtech industry is thriving, according to consulting firm McKinsey’s “M&A Annual Report: Is the Wave Finally Arriving?”

In 2024, the medtech industry experienced its most active year for portfolio-shaping activity since 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Market Intelligence